全球Duchenne氏肌肉失養症患者人數分析與預測（2026-2035 年）

Duchenne氏肌肉失養症（DMD）是一種罕見的、進行性的X連鎖神經肌肉疾病，由Dystrophin基因突變引起，導致嚴重的肌肉萎縮、行走能力喪失、呼吸系統併發症、心肌病和過早死亡。此病主要影響男性，是兒童最常見的遺傳性神經肌肉疾病之一。儘管DMD仍然是一種罕見疾病，但診斷、疾病管理和支持治療的進步正導致全球患者數量增加。

患者群體分析在了解疾病負擔、預測未來治療需求、支持臨床試驗規劃、指導醫療資源分配以及幫助製藥公司評估商業性機會方面發揮著至關重要的作用。隨著基因療法、外顯子跳躍藥物和突變特異性療法等創新療法的出現，準確的患者群體預測在整個杜氏肌肉營養不良症（DMD）生態系統中變得日益重要。

市場促進因素

基因診斷的廣泛應用

市場成長的主要驅動力之一是先進基因檢測技術的廣泛應用。分子診斷、次世代定序和新生兒篩檢計畫的進步使得早期準確識別杜氏肌肉營養不良症（DMD）患者成為可能。

早期診斷改善了疾病管理，導致流行病學資料庫和患者登記冊中登記的患者數量增加。

提高患者存活率

由於多學科護理、呼吸支持、心臟管理、皮質類固醇療法以及新的疾病修正治療的進步，DMD 患者的生存率已顯著提高。

隨著平均壽命的延長，患者數量持續增加，導致對長期流行病學監測和預測的需求日益成長。

擴大罕見疾病登記範圍

透過國內外患者登記系統，DMD流行病學數據的品質正在不斷提高。這些登記系統有助於識別患者、進行自然病程研究、招募臨床試驗參與者以及製定醫療保健計劃。

增加對真實世界數據 (REW) 收集和患者追蹤系統的投入，進一步增強了我們的人口分析能力。

精準醫療的需求日益成長

開發特異性特定突變的療法需要詳細了解患者亞群、基因譜、疾病階段和區域流行模式。

分析患者群體對於確定合格的治療群體和支持商業化策略變得越來越重要。

市場限制因素

新興市場缺乏診斷技術

許多中低收入國家仍面臨基因檢測和專科護理機會有限以及疾病認知度低等挑戰。

因此，相當數量的 DMD 患者可能仍未得到診斷，這可能會導致流行病學估計值的不確定性。

資料收集的變異性

由於登記資料的全面性、醫療報告系統、診斷標準和流行病學調查方法存在差異，不同地區和資料集之間可能會出現不一致的情況。

患者數量少

由於 DMD 是一種罕見疾病，全球受影響的人數相對有限，這給收集大規模流行病學數據和預測長期趨勢帶來了挑戰。

流行病學和患者族群調查結果

儘管與其它慢性疾病相比，全球 DMD 患者的數量仍然相對較少，但對患者、他們的家庭和醫療保健系統造成的負擔卻是巨大的。

近期流行病學分析估計，全球DMD盛行率約為每10萬名男性7.1例，一般人群盛行率約每10萬人2.8例。出生盛行率估計約為每10萬名男性19.8例。

產業預測顯示，全球杜氏肌肉營養不良症（DMD）患者人數將從2026年的約43萬增加到2035年的約54萬，年複合成長率約為2.5%。這一成長主要歸功於診斷技術的進步、人們對該疾病認知的提高以及患者生存期的延長。

據估計，迄今為止，全球每 3500 至 5000 名男孩中約有 1 人患有 DMD，使其成為兒童中最常見的遺傳性神經肌肉疾病之一。

目錄

第1章執行摘要

第2章 疾病與流行病學分析

• Duchenne氏肌肉失養症簡介
• 疾病生物學
• 風險因子和病因
• 臨床症狀
• 診斷和篩檢
• 流行病學分析

第3章 市場動態

• 市場概覽
• 市場促進因素
• 市場限制因素
• 市場機遇
• 波特五力分析

第4章 商業和市場進入

• 市場進入概覽
• 還款系統狀態
• 已通過核准療法的價格分析
• 患者支持計劃
• 罕見疾病資助舉措
• 醫療基礎設施和治療機會

第5章：創新與通路展望

• DMD領域的創新趨勢
• 按開發階段分類的管道概覽
• 按作用機制分類的管道概覽
• 按治療方式分類的管道概覽

第6章 當前治療狀況

• 目前治療模式
• 標準治療
• 已批准治療方案概述
• 治療流程
• 新的治療方法
• 現有治療方法的比較分析

第7章：全球Duchenne氏肌肉失養症患者群體的分析、規模和預測。

• 市場概覽
• 歷史市場規模分析
• 市場規模預測分析
• 按治療類型分類的市場規模
• 按給藥途徑分類的市場規模
• 按分銷通路分類的市場規模
• 按最終用戶分類的市場規模
• 市場吸引力分析

第8章：Duchenne氏肌肉失養症患者群體的全球分析與細分

• 治療類型
• 透過行政途徑
• 按患者年齡層別分類
• 護理環境
• 透過分銷管道

第9章 區域分析（區域層級）

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲

第10章：主要國家分析

• 加拿大
• 德國
• 中國
• 日本
• 印度

第11章 法規與政策概述

• 監管概述
• 罕見疾病的監管途徑
• 孤兒藥認定框架
• 美國法規結構（FDA）
• 歐洲法規結構（EMA）
• 日本的法規結構（藥品和醫療設備管理局）
• 印度的法規結構（CDSCO）
• 中國的法規結構（NMPA）
• 贖回和市場進入政策
• 罕見疾病患者權益倡導及相關政策

第12章 競爭格局

• 市佔率分析
• 競爭性標竿分析
• 產品系列分析
• 管道競爭力分析
• 策略合作與夥伴關係
• 併購
• 授權協議
• 近期趨勢

第13章：公司簡介

• Sarepta Therapeutics
• PTC Therapeutics
• Santhera Pharmaceuticals
• NS Pharma
• Italfarmaco
• Dyne Therapeutics
• REGENXBIO
• Solid Biosciences
• Wave Life Sciences
• PepGen

第14章 未來展望

• 患者群體未來發展趨勢
• 基因篩檢計劃的演變
• 基因療法引入的影響
• 新興技術和精準醫療
• 治療諮詢率預測
• 策略建議

第15章：調查方法

Duchenne Muscular Dystrophy (DMD) is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene, leading to severe muscle degeneration, loss of ambulation, respiratory complications, cardiomyopathy, and premature mortality. The disease primarily affects males and is among the most common inherited neuromuscular disorders in children. Although DMD remains a rare disease, improvements in diagnosis, disease management, and supportive care are contributing to a growing prevalent patient population worldwide.

Patient population analysis plays a critical role in understanding disease burden, forecasting future treatment demand, supporting clinical trial planning, guiding healthcare resource allocation, and enabling pharmaceutical companies to assess commercial opportunities. As innovative therapies such as gene therapies, exon-skipping drugs, and mutation-specific treatments continue to emerge, accurate patient population forecasting has become increasingly important across the DMD ecosystem.

Market Drivers

Increasing Adoption of Genetic Diagnostics

One of the primary drivers of market growth is the widespread adoption of advanced genetic testing technologies. Improvements in molecular diagnostics, next-generation sequencing, and newborn screening programs are enabling earlier and more accurate identification of DMD patients.

Earlier diagnosis improves disease management and increases the number of identified patients within epidemiological databases and patient registries.

Growing Patient Survival Rates

Advances in multidisciplinary care, respiratory support, cardiac management, corticosteroid treatment, and emerging disease-modifying therapies have significantly improved survival outcomes for DMD patients.

As life expectancy increases, the prevalent patient population continues to expand, creating greater demand for long-term epidemiological monitoring and forecasting.

Expansion of Rare Disease Registries

National and international patient registries are improving the quality of DMD epidemiological data. These registries facilitate patient identification, natural history studies, clinical trial recruitment, and healthcare planning activities.

Growing investments in real-world evidence generation and patient tracking systems are further strengthening population analysis capabilities.

Rising Demand for Precision Medicine

The development of mutation-specific therapies requires detailed understanding of patient subgroups, genetic profiles, disease stages, and regional prevalence patterns.

Patient population analysis is becoming increasingly important for identifying eligible treatment populations and supporting commercialization strategies.

Market Restraints

Underdiagnosis in Emerging Markets

Many low- and middle-income countries continue to face challenges related to limited access to genetic testing, specialist care, and disease awareness.

As a result, a significant number of DMD patients may remain undiagnosed, creating uncertainty in epidemiological estimates.

Variability in Data Collection

Differences in registry coverage, healthcare reporting systems, diagnostic criteria, and epidemiological methodologies can lead to inconsistencies across regions and datasets.

Small Patient Population

As a rare disease, DMD affects a relatively limited number of individuals globally, creating challenges in collecting large-scale epidemiological data and forecasting long-term trends.

Epidemiology and Patient Population Insights

The global DMD patient population remains relatively small compared with common chronic diseases, but the burden on patients, families, and healthcare systems is substantial.

Recent epidemiological analyses estimate that the global prevalence of DMD is approximately 7.1 cases per 100,000 males and 2.8 cases per 100,000 individuals in the general population. Birth prevalence has been estimated at approximately 19.8 cases per 100,000 live male births.

According to industry forecasts, the global DMD patient population is expected to increase from approximately 0.43 million patients in 2026 to approximately 0.54 million patients by 2035, representing a compound annual growth rate (CAGR) of around 2.5%. This growth is primarily attributed to improved diagnosis, increased disease awareness, and longer patient survival.

Historically, DMD has been estimated to affect approximately one in every 3,500-5,000 live male births globally, making it one of the most common inherited neuromuscular disorders among children.

Technology and Segment Insights

The global DMD patient population analysis market can be segmented by patient type, age group, mutation profile, disease stage, data source, end user, and geography.

By patient type, the market includes diagnosed patients, treated patients, untreated patients, ambulatory patients, and non-ambulatory patients. Diagnosed patient populations continue to grow due to improvements in genetic testing and disease awareness.

By age group, the market includes pediatric patients, adolescent patients, and adult patients. Pediatric patients currently account for the largest share of the DMD population, although increasing life expectancy is contributing to growth in adult patient segments.

By mutation profile, patient populations can be categorized according to exon-specific mutations and genetic abnormalities. These classifications are becoming increasingly important as personalized therapies target specific mutation groups.

By disease stage, the market includes early-stage, ambulatory, transitional, non-ambulatory, and advanced-stage patients. Disease-stage analysis supports treatment planning, healthcare resource allocation, and clinical trial design.

By data source, the market includes patient registries, hospital databases, electronic health records, genetic testing databases, insurance claims databases, and epidemiological studies.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, research organizations, academic institutions, contract research organizations, and government agencies.

Advancements in artificial intelligence, predictive analytics, digital health platforms, and real-world evidence technologies are improving patient identification, disease tracking, and long-term population forecasting.

Regional Insights

North America remains a leading region for DMD patient population analysis due to advanced diagnostic infrastructure, strong rare disease awareness, established patient registries, and extensive clinical research activity.

Europe represents a significant market supported by robust healthcare systems, comprehensive patient registries, and active rare disease initiatives. Several European countries maintain well-established neuromuscular disease surveillance programs.

Asia-Pacific is expected to witness the fastest growth in patient identification and epidemiological monitoring. Improvements in healthcare infrastructure, expanding genetic testing availability, and growing awareness of rare diseases are contributing to increased diagnosis rates across countries such as China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving diagnostic capabilities and rare disease surveillance, although access to specialized care remains uneven across several regions.

Competitive and Strategic Outlook

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, patient registry operators, rare disease research institutions, pharmaceutical companies, biotechnology firms, and healthcare consulting organizations.

Market participants are increasingly investing in patient registry expansion, real-world evidence generation, digital disease surveillance platforms, and advanced epidemiological analytics. Strategic collaborations among industry stakeholders, healthcare providers, academic institutions, and patient advocacy groups continue to improve data quality and patient identification.

Growing interest in mutation-specific therapies and gene therapies is also increasing demand for highly detailed patient segmentation and forecasting capabilities.

Conclusion

The global Duchenne Muscular Dystrophy patient population analysis market is poised for sustained growth through 2035, supported by expanding diagnostic capabilities, increasing disease awareness, improving survival outcomes, and growing investment in rare disease research. As the global DMD patient population is projected to increase from approximately 0.43 million patients in 2026 to approximately 0.54 million patients by 2035, accurate patient population forecasting will become increasingly important for healthcare planning, clinical development, and commercialization strategies. While challenges related to underdiagnosis and data variability remain, advances in genetic diagnostics, patient registries, real-world evidence platforms, and digital health technologies are expected to significantly enhance future epidemiological analysis and disease monitoring capabilities.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of global DMD prevalence, incidence, diagnosed population, and future patient trends.
• Competitive Landscape: Understand epidemiological developments, patient registry expansion, and emerging rare disease initiatives.
• Market Drivers and Future Trends: Assess factors influencing patient population growth and disease identification.
• Actionable Recommendations: Support healthcare planning, clinical development, commercialization, and investment decisions.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, consultants, and policy stakeholders.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological assessment, clinical trial planning, market opportunity evaluation, healthcare resource planning, rare disease strategy development, investment analysis, and commercialization planning.

Report Coverage

• Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
• Global, regional, and country-level patient population analysis and forecasts
• Prevalence, incidence, diagnosed population, and mutation-specific patient segmentation
• Disease-stage assessment, demographic analysis, and epidemiological trends
• Competitive intelligence, patient registry analysis, and future market opportunity assessment.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Overview of Duchenne Muscular Dystrophy (DMD)
• 1.2 Key Epidemiology Highlights
• 1.3 Patient Population Overview by Region
• 1.4 Major Findings and Strategic Insights
• 1.5 Emerging Trends Influencing Patient Identification and Management
• 1.6 Future Outlook

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Duchenne Muscular Dystrophy
  • 2.1.1 Disease Definition
  • 2.1.2 Historical Background
  • 2.1.3 Disease Burden and Unmet Needs
• 2.2 Disease Biology
  • 2.2.1 Genetics and Dystrophin Gene Mutations
  • 2.2.2 Pathophysiology
  • 2.2.3 Disease Progression Stages
• 2.3 Risk Factors and Etiology
  • 2.3.1 Genetic Causes
  • 2.3.2 Family History and Carrier Status
  • 2.3.3 Other Contributing Factors
• 2.4 Clinical Presentation
  • 2.4.1 Early Symptoms
  • 2.4.2 Motor and Functional Decline
  • 2.4.3 Cardiac and Respiratory Complications
  • 2.4.4 Cognitive and Behavioral Manifestations
• 2.5 Diagnosis and Screening
  • 2.5.1 Clinical Assessment
  • 2.5.2 Creatine Kinase Testing
  • 2.5.3 Genetic Testing
  • 2.5.4 Muscle Biopsy
  • 2.5.5 Newborn Screening Initiatives
• 2.6 Epidemiology Analysis
  • 2.6.1 Incidence of DMD
  • 2.6.2 Prevalence of DMD
  • 2.6.3 Diagnosed Prevalent Cases
  • 2.6.4 Age-wise Patient Population
  • 2.6.5 Gender-wise Patient Population
  • 2.6.6 Mutation-specific Patient Population
    • 2.6.6.1 Exon 51 Skipping Amenable Population
    • 2.6.6.2 Exon 53 Skipping Amenable Population
    • 2.6.6.3 Exon 45 Skipping Amenable Population
    • 2.6.6.4 Other Mutation Types
  • 2.6.7 Disease Severity-wise Patient Population
  • 2.6.8 Treated vs Untreated Patient Population

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Increasing Genetic Testing and Early Diagnosis
  • 3.2.2 Growing Awareness of Rare Diseases
  • 3.2.3 Advancements in Gene Therapy
  • 3.2.4 Expansion of Newborn Screening Programs
• 3.3 Market Restraints
  • 3.3.1 High Cost of Therapy
  • 3.3.2 Limited Patient Accessibility
  • 3.3.3 Regulatory Challenges
  • 3.3.4 Small Patient Pool
• 3.4 Market Opportunities
  • 3.4.1 Precision Medicine Approaches
  • 3.4.2 Emerging Gene Editing Technologies
  • 3.4.3 Expansion in Emerging Markets
  • 3.4.4 Improved Carrier Screening Programs
• 3.5 Porter's Five Forces Analysis
  • 3.5.1 Threat of New Entrants
  • 3.5.2 Bargaining Power of Suppliers
  • 3.5.3 Bargaining Power of Buyers
  • 3.5.4 Threat of Substitutes
  • 3.5.5 Competitive Rivalry

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Reimbursement Landscape
• 4.3 Pricing Analysis of Approved Therapies
• 4.4 Patient Assistance Programs
• 4.5 Rare Disease Funding Initiatives
• 4.6 Healthcare Infrastructure and Treatment Accessibility

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends in DMD
  • 5.1.1 Gene Replacement Therapy
  • 5.1.2 Exon Skipping Technologies
  • 5.1.3 Gene Editing Approaches
  • 5.1.4 Muscle Regeneration Therapies
  • 5.1.5 Anti-inflammatory and Supportive Therapies
• 5.2 Pipeline Landscape by Development Stage
  • 5.2.1 Phase I Pipeline Candidates
  • 5.2.2 Phase II Pipeline Candidates
  • 5.2.3 Phase III Pipeline Candidates
• 5.3 Pipeline Landscape by Mechanism of Action
  • 5.3.1 Micro-dystrophin Gene Therapy
  • 5.3.2 Exon Skipping Therapy
  • 5.3.3 Histone Deacetylase Inhibition
  • 5.3.4 Gene Editing Technologies
  • 5.3.5 Muscle Preservation Therapies
• 5.4 Pipeline Landscape by Modality
  • 5.4.1 Gene Therapies
  • 5.4.2 Antisense Oligonucleotides
  • 5.4.3 Small Molecules
  • 5.4.4 Biologics

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Standard of Care
  • 6.2.1 Corticosteroids
  • 6.2.2 Cardiac Management
  • 6.2.3 Respiratory Management
  • 6.2.4 Physical Therapy and Rehabilitation
• 6.3 Approved Therapies Overview
  • 6.3.1 Gene Therapies
  • 6.3.2 Exon Skipping Therapies
  • 6.3.3 Corticosteroid Therapies
  • 6.3.4 Histone Deacetylase Inhibitors
• 6.4 Treatment Algorithm
• 6.5 Emerging Treatment Approaches
• 6.6 Comparative Analysis of Available Therapies

7. Global Duchenne Muscular Dystrophy Patient Population Analysis Size & Forecast

• 7.1 Market Overview
• 7.2 Historical Market Size Analysis
• 7.3 Forecast Market Size Analysis
• 7.4 Market Size by Therapy Type
• 7.5 Market Size by Route of Administration
• 7.6 Market Size by Distribution Channel
• 7.7 Market Size by End User
• 7.8 Market Attractiveness Analysis

8. Global Duchenne Muscular Dystrophy Patient Population Analysis Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Gene Therapy
  • 8.1.2 Exon Skipping Therapy
  • 8.1.3 Corticosteroids
  • 8.1.4 Supportive Therapies
• 8.2 By Route of Administration
  • 8.2.1 Intravenous
  • 8.2.2 Oral
  • 8.2.3 Others
• 8.3 By Patient Age Group
  • 8.3.1 Pediatric
  • 8.3.2 Adolescent
  • 8.3.3 Adult
• 8.3 By Care Setting
  • 8.3.1 Hospitals
  • 8.3.2 Specialty Clinics
  • 8.3.3 Home Care Settings
• 8.4 By Distribution Channel
  • 8.4.1 Hospital Pharmacies
  • 8.4.2 Retail & Specialty Pharmacies
  • 8.4.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Epidemiology Overview
  • 9.1.3 Demand Drivers
  • 9.1.4 Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Epidemiology Overview
  • 9.2.3 Demand Drivers
  • 9.2.4 Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Epidemiology Overview
  • 9.3.3 Demand Drivers
  • 9.3.4 Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Epidemiology Overview
  • 9.4.3 Demand Drivers
  • 9.4.4 Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Epidemiology Overview
  • 9.5.3 Demand Drivers
  • 9.5.4 Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 Rare Disease Regulatory Pathways
• 11.3 Orphan Drug Designation Framework
• 11.4 United States Regulatory Framework (FDA)
• 11.5 Europe Regulatory Framework (EMA)
• 11.6 Japan Regulatory Framework (PMDA)
• 11.7 India Regulatory Framework (CDSCO)
• 11.8 China Regulatory Framework (NMPA)
• 11.9 Reimbursement and Market Access Policies
• 11.10 Patient Advocacy and Rare Disease Policies

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Analysis
• 12.4 Pipeline Competitiveness Analysis
• 12.5 Strategic Collaborations and Partnerships
• 12.6 Mergers and Acquisitions
• 12.7 Licensing Agreements
• 12.8 Recent Developments

13. Company Profiles

• 13.1 Sarepta Therapeutics
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products
    • 13.1.2.1 Elevidys (delandistrogene moxeparvovec-rokl)
    • 13.1.2.2 Exondys 51 (eteplirsen)
    • 13.1.2.3 Vyondys 53 (golodirsen)
    • 13.1.2.4 Amondys 45 (casimersen)
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Portfolio
  • 13.1.5 Recent Developments
• 13.2 PTC Therapeutics
  • 13.2.1 Company Overview
  • 13.2.2 Approved Products
    • 13.2.2.1 Emflaza (deflazacort)
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Portfolio
  • 13.2.5 Recent Developments
• 13.3 Santhera Pharmaceuticals
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products
    • 13.3.2.1 Agamere (vamorolone)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Portfolio
  • 13.3.5 Recent Developments
• 13.4 NS Pharma
  • 13.4.1 Company Overview
  • 13.4.2 Approved Products
    • 13.4.2.1 Viltepso (viltolarsen)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Portfolio
  • 13.4.5 Recent Developments
• 13.5 Italfarmaco
  • 13.5.1 Company Overview
  • 13.5.2 Approved Products
    • 13.5.2.1 Duvyzat (givinostat)
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Portfolio
  • 13.5.5 Recent Developments
• 13.6 Dyne Therapeutics
  • 13.6.1 Company Overview
  • 13.6.2 Pipeline Portfolio
    • 13.6.2.1 DYNE-251 (Phase II)
  • 13.6.3 Key Indications
  • 13.6.4 Recent Developments
• 13.7 REGENXBIO
  • 13.7.1 Company Overview
  • 13.7.2 Pipeline Portfolio
    • 13.7.2.1 RGX-202 (Phase I/II)
  • 13.7.3 Key Indications
  • 13.7.4 Recent Developments
• 13.8 Solid Biosciences
  • 13.8.1 Company Overview
  • 13.8.2 Pipeline Portfolio
    • 13.8.2.1 SGT-003
  • 13.8.3 Key Indications
  • 13.8.4 Recent Developments
• 13.9 Wave Life Sciences
  • 13.9.1 Company Overview
  • 13.9.2 Pipeline Portfolio
    • 13.9.2.1 WVE-N531
  • 13.9.3 Key Indications
  • 13.9.4 Recent Developments
• 13.10 PepGen
  • 13.10.1 Company Overview
  • 13.10.2 Pipeline Portfolio
    • 13.10.2.1 PGN-EDO51
  • 13.10.3 Key Indications
  • 13.10.4 Recent Developments

14. Future Outlook

• 14.1 Future Patient Population Trends
• 14.2 Evolution of Genetic Screening Programs
• 14.3 Impact of Gene Therapy Adoption
• 14.4 Emerging Technologies and Precision Medicine
• 14.5 Forecast of Treatment Uptake
• 14.6 Strategic Recommendations

15. Methodology

• 15.1 Research Scope and Objectives
• 15.2 Data Collection Methodology
• 15.3 Epidemiology Modeling Approach
• 15.4 Secondary Research Sources
• 15.5 Primary Research Methodology
• 15.6 Market Forecasting Methodology
• 15.7 Assumptions and Limitations
• 15.8 Abbreviations and Definitions